Purple Begin Period Cash Flow from 2010 to 2024
| PPBT Stock | USD 2.74 0.55 25.11% |
Begin Period Cash Flow | First Reported 2014-09-30 | Previous Quarter 10 M | Current Value 6.5 M | Quarterly Volatility 7.9 M |
Check Purple Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Purple Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 208.9 K, Interest Expense of 2.3 M or Selling General Administrative of 4.6 M, as well as many indicators such as Price To Sales Ratio of 84.89, Dividend Yield of 0.088 or PTB Ratio of 0.49. Purple financial statements analysis is a perfect complement when working with Purple Biotech Valuation or Volatility modules.
Purple | Begin Period Cash Flow |
Latest Purple Biotech's Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Purple Biotech over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Purple Biotech's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Purple Biotech's overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Purple Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 5,193,283 | |
| Geometric Mean | 1,994,923 | |
| Coefficient Of Variation | 95.64 | |
| Mean Deviation | 4,128,873 | |
| Median | 4,385,000 | |
| Standard Deviation | 4,966,819 | |
| Sample Variance | 24.7T | |
| Range | 14.8M | |
| R-Value | 0.81 | |
| Mean Square Error | 9T | |
| R-Squared | 0.66 | |
| Significance | 0.0002 | |
| Slope | 901,927 | |
| Total Sum of Squares | 345.4T |
Purple Begin Period Cash Flow History
About Purple Biotech Financial Statements
Purple Biotech shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Purple Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Purple Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Purple Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 15 M | 7.6 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.